BRPI0718120A2 - Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer - Google Patents

Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer Download PDF

Info

Publication number
BRPI0718120A2
BRPI0718120A2 BRPI0718120-5A BRPI0718120A BRPI0718120A2 BR PI0718120 A2 BRPI0718120 A2 BR PI0718120A2 BR PI0718120 A BRPI0718120 A BR PI0718120A BR PI0718120 A2 BRPI0718120 A2 BR PI0718120A2
Authority
BR
Brazil
Prior art keywords
amino
cyclopentyl
ethyl
methyl
tert
Prior art date
Application number
BRPI0718120-5A
Other languages
English (en)
Portuguese (pt)
Inventor
David Festus Charles Moffat
Sanjay Ratilal Patel
Stephen John Davies
Kenneth William John Baker
Oliver James Philips
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of BRPI0718120A2 publication Critical patent/BRPI0718120A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0718120-5A 2006-10-25 2007-10-19 Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer BRPI0718120A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0621205.4 2006-10-25
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
GB0715614.4 2007-08-10
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0718120A2 true BRPI0718120A2 (pt) 2013-11-12

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718120-5A BRPI0718120A2 (pt) 2006-10-25 2007-10-19 Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer

Country Status (13)

Country Link
US (1) US20100216802A1 (https=)
EP (1) EP2079743B1 (https=)
JP (1) JP2010507639A (https=)
KR (1) KR20090071668A (https=)
AT (1) ATE542820T1 (https=)
AU (1) AU2007310604B2 (https=)
BR (1) BRPI0718120A2 (https=)
CA (1) CA2665736A1 (https=)
EA (1) EA200900593A1 (https=)
IL (1) IL198082A0 (https=)
MX (1) MX2009004244A (https=)
NZ (1) NZ577153A (https=)
WO (1) WO2008050096A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
US8962825B2 (en) * 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
MX2009006345A (es) 2006-12-14 2009-06-23 Vertex Pharma Compuestos utiles como inhibidores de proteina cinasa.
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
WO2010008459A1 (en) * 2008-06-23 2010-01-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
MX2011000026A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
WO2011026241A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
HUE046132T2 (hu) 2012-10-17 2020-02-28 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluor-benzoil)-2-oxopiridin-1(2H)-il]-3,5-difluor-fenil}etil]-l-alanin és annak tercbutil-észtere
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015117055A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
US20230263783A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) * 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用

Also Published As

Publication number Publication date
US20100216802A1 (en) 2010-08-26
CA2665736A1 (en) 2008-05-02
AU2007310604A1 (en) 2008-05-02
EA200900593A1 (ru) 2010-06-30
WO2008050096A1 (en) 2008-05-02
EP2079743A1 (en) 2009-07-22
EP2079743B1 (en) 2012-01-25
MX2009004244A (es) 2009-05-14
IL198082A0 (en) 2009-12-24
NZ577153A (en) 2012-02-24
ATE542820T1 (de) 2012-02-15
KR20090071668A (ko) 2009-07-01
JP2010507639A (ja) 2010-03-11
AU2007310604B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
BRPI0718120A2 (pt) Derivados de pteridina como inibidores de cinase do tipo pólo úteis no tratamento de câncer
EP4054719B1 (en) Ras inhibitors
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
ES2522365T3 (es) Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
US20110190306A1 (en) Inhibitors of PLK
CA3258898A1 (en) MACROCYCLICAL RAS INHIBITORS
CA2862940C (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
IL301298A (en) Indole derivatives as RAS inhibitors in cancer therapy
US20260028353A1 (en) Macrocyclic ras inhibitors
ES2955206T3 (es) Derivados de espiroquinoxalina como inhibidores de la muerte celular regulada no apoptótica
BR112017003433B1 (pt) Inibidores espirocíclicos de catepsina c, composição farmacêutica e uso dos mesmos
ES2912035T3 (es) Compuestos
BR112016014151B1 (pt) Pirirmidopirimidinonas úteis como inibidores de quinases wee-1
CN101998959A (zh) 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
NZ729137A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
ES2671322T3 (es) Derivados de piperidin urea
BR112020019560A2 (pt) Moduladores de calpaína e usos terapêuticos dos mesmos
CN116783183A (zh) 作为vhl抑制剂用于治疗贫血和癌症的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
BRPI0621509A2 (pt) modulação da atividade de fosforil transferase de glutamina sintetase
CN101541800A (zh) 用于治疗癌症的作为plk抑制剂的蝶啶衍生物
WO2009141575A1 (en) Inhibitors of plk
BR112022008565B1 (pt) Compostos e composições farmacêuticas
BR122023011393B1 (pt) Composto, composição farmacêutica e usos de um composto
HK40076674A (en) Ras inhibitors
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2277 DE 26/08/2014.

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: ARQUIVAMENTO DEFINITIVO

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2292 DE 09/12/2014.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.